Replies to post #259463 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I didn't ask Clint about the status of data lock.. I asked him if he had said it hadn't occurred. I quoted him as saying he "had no certain knowledge".

The other poster today claimed that it hadn't occurred.

Jager's post contains no quotes, he may have inferred that the data was locked and on schedule. I was only told that the schedule for data release had not changed, and from that I would also infer that data lock had probably occurred some time in the past. Nothing that was said today led me to believe that the anticipated release of PDD data would be delayed.

Jager997 Saturday, 06/27/20 03:40:00 PM
Re: nidan7500 post# 256491 0
Post #
256562
of 259465
To briefly summarize my conversation with IR:
Jager - I have been an investor with AVXL for approximately 5 years… What’s up?
IR – Dr. Missling said the approach other companies have taken with Alzheimer’s disease has failed. That is when he decided to use biomarkers and discovered a couple that seem to respond better to the drug. Of course this approach is taking longer. We are also expanding the trials to include Canada and the UK.
Jager – I expected to hear approval of some kind from the Australian Government by now.
IR – They are waiting on test results from the studies.
Jager - When are you going to provide results from the Parkinson’s study?
IR – I don’t have an exact date but sometime this summer, June, July, or August. Although not likely June since we are at the end of the month. The data is locked but it will take some time to analyze and review the data.
Jager – Have you looked into treating Glaucoma?
IR – Yes we have. But since we are a small company, and running three trials, it would be too much to take on at this time.
Jager – Back some time ago I recall Dr. Missling mentioning you would probably partner going into large scale trial with Alzheimer, phase three study… Is that still on the table?
IR – We want to maintain good value to our shareholders. If we partner with someone part of the proceeds will have to go to the partner. We feel that we can take Rett Syndrome and Parkinson’s treatment to market but would probably need to partner with a manufacturer to meet Alzheimer treatment.
Jager – Thank you for your time. I am looking forward to the Parkinson’s results.
IR – It should be a good summer with the Parkinson’s results followed by the Rett Syndrome results shortly thereafter.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156566647&txt2find=data|lock